Influenza medication market is expected to grow at a significant CAGR during the forecast period. Over the last few decades, the number of severe and life-threatening infectious diseases has increased across the globe. There are various kinds of influenza, which have exhibited a steady increase in occurrence globally. In October 2019, there were 9.7 million influenza cases in the US, according to the Centers for Disease Control and Prevention (CDC). This, in turn, is driving the growth of the market.
The major companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, and new product launches to remain competitive in the marketplace. For instance, in October 2019, Xofluza (Baloxavir Marboxil) was approved by the FDA for people who are at a high risk of suffering from influenza-related complications. Shionogi & Co., Ltd. stated in October 2019 that a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the postexposure prophylaxis of influenza virus infection had been filed in Japan. Further, Shionogi & Co., Ltd. announced in August 2019 that Xofluza (Baloxavir Marboxil) 20mg tablets have been approved in Taiwan for the treatment of influenza types A and B in individuals over the age of 12. Xofluza is a first-in-class, single-dose oral drug with a new mechanism of action that inhibits polymerase acidic endonuclease, a viral replication enzyme.
In November, 2020, Shionogi & Co., Ltd. announced that F. Hoffmann-La Roche Ltd., which holds global rights to Xofluza except in Japan and Taiwan, has received FDA approval for a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone who has influenza (known as post-exposure prophylaxis). In November 2020, Roche announced that the FDA has granted a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) as a therapy to prevent influenza in patients aged 12 and up who have been exposed to influenza (known as post-exposure prophylaxis).
To Request a Sample of our Report on Influenza Medication Market: https://www.omrglobal.com/request-sample/influenza-medication-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
Segment Covered-
- By Product
- By Distribution Channel
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: CSL Ltd., F. Hoffmann-La Roche Ltd., and GlaxoSmithKline plc, among others.
Influenza Medication Market Report by Segment
By Product
- Baloxavir (Marboxil)
- Zanamivir
- Oseltamivir
- Peramivir
- Amantadine
- Other (Rimantadine)
By Distribution Channel
- Hospitals
- Clinics
- Pharmacies
- Others
A full Report of Influenza Medication Market is Available @ https://www.omrglobal.com/industry-reports/influenza-medication-market
Influenza Medication Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
